Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2005
03/10/2005CA2536911A1 Antibody against nox1 polypeptide, method of diagnosing cancer with the use of nox1 gene and method of screening cancer growth inhibitor
03/10/2005CA2536910A1 Oral neurotherapeutic cefazolin compositions
03/10/2005CA2536906A1 Compositions for treating pathologies that necessitate suppression of gastric acid secretion
03/10/2005CA2536902A1 Proton pump inhibitor formulations, and methods of preparing and using such formulations
03/10/2005CA2536871A1 Chroman carboxylic acid derivatives for the treatment of diabetes and lipid disorders
03/10/2005CA2536842A1 Benzotropolone derivatives and modulation of inflammatory response
03/10/2005CA2536788A1 Naphthalene carboxamides and their derivatives useful as new anti-angiogenic agents
03/10/2005CA2536786A1 Substituted heterocyclic compounds and methods of use
03/10/2005CA2536784A1 Process for the production of polymorphs of rosiglitazone maleate
03/10/2005CA2536738A1 Aerosol delivery of curcumin
03/10/2005CA2536582A1 Intranasal opioid compositions
03/10/2005CA2536578A1 Methods related to the treatment of mucosal associated conditions
03/10/2005CA2536570A1 Novel peptidomimetic ns3-serine protease inhibitors of hepatitis c virus
03/10/2005CA2536553A1 Substituted 8-heteroaryl xanthines
03/10/2005CA2536507A1 Stepwise delivery of topiramate over prolonged period of time
03/10/2005CA2536466A1 Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
03/10/2005CA2536461A1 Aryl piperidine amides
03/10/2005CA2536459A1 Pentafluorosulfanyl phenyl-substituted benzoylguanidines, method for their production, their use as medicaments or diagnostic agents and medicament containing said compounds
03/10/2005CA2536458A1 Composition comprising a pulmonary surfactant and a pde2 inhibitor
03/10/2005CA2536453A1 Use of surfactant preparations for the treatment of surgical adhesions
03/10/2005CA2536432A1 Combination therapy for glycaemic control
03/10/2005CA2536415A1 Crosslinking reagent for treating intervertebral disc disorders
03/10/2005CA2536378A1 Rifamycin analogs and uses thereof
03/10/2005CA2536321A1 Thienopyridine-phenylacet amides and their derivatives useful as new anti-angiogenic agents
03/10/2005CA2536249A1 Delivery of immune response modifier compounds
03/10/2005CA2536247A1 Cellular depolarization and regulation of matrix metalloproteinases
03/10/2005CA2536246A1 Skeletally targeted nanoparticles
03/10/2005CA2536205A1 Human obesity susceptibility gene and uses thereof
03/10/2005CA2536191A1 Nanoparticles for delivery of nucleic acids and stable double-stranded rna
03/10/2005CA2536184A1 Use of bisphosphonates for otosclerosis
03/10/2005CA2536174A1 N3-substituted imidazopyridine-derivatives as c-kit inhibitors
03/10/2005CA2536161A1 Treatment of pervasive developmental disorders with norepinephrine reuptake inhibitors
03/10/2005CA2536151A1 N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors
03/10/2005CA2535923A1 Formulations and methods of treating inflammatory bowel disease
03/10/2005CA2535896A1 N-substituted benzimidazolyl c-kit inhibitors
03/10/2005CA2535686A1 Proteasome inhibitors and methods of using the same
03/10/2005CA2535527A1 Immunogenic hiv compositions and related methods
03/10/2005CA2535265A1 Compositions and methods for the treatment of disease associated with trp-p8 expression
03/10/2005CA2534831A1 .delta.15-d-homosteroids having an androgenic effect
03/10/2005CA2533690A1 Use of a polyamine-poor composition for the production of a medical human food
03/10/2005CA2533570A1 Synergistic antioxidant compositions comprising hydrophobic and hydrophillic antioxidants
03/10/2005CA2533175A1 5-phenyl-4-methyl-thiazol-2-yl-amine derivatives as inhibitors of phosphatidylinositol 3 kinase enzymes (pi3) for the treatment of inflammatory airway diseases
03/10/2005CA2532349A1 Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors
03/10/2005CA2531768A1 Chrna2 genetic markers associated with galantamine response
03/10/2005CA2531506A1 Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases
03/10/2005CA2530014A1 Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors
03/10/2005CA2529027A1 D-amino acid peptides
03/10/2005CA2528059A1 Control of protozoa and protozoan cysts that harbor legionella
03/10/2005CA2525374A1 Delivery of compounds with rehydrated blood cells
03/10/2005CA2510677A1 Amino acid derived prodrugs of propofol, compositions and uses thereof
03/10/2005CA2440445A1 Oral treatment for anorectal conditions
03/09/2005EP1512689A1 Process for producing 3-cephem compounds
03/09/2005EP1512688A1 Use of K-252a derivatives for the treatment of Parkinson's disease
03/09/2005EP1512686A1 Imidazonaphthyridines and their use in inducing cytokine biosythesis
03/09/2005EP1512685A1 Imidazonaphthyridines and their use in inducing cytokine biosythesis
03/09/2005EP1512683A1 Novel opiate compounds, methods of making and methods of use
03/09/2005EP1512679A1 Novel adamantane derivatives with neuroprotective, antidepressant and anti-ischaemic activities, and process for preparing them
03/09/2005EP1512415A1 Decoy composition for treating and preventing inflammatory disease
03/09/2005EP1512414A1 Hapten-carrier conjugates for treating and preventing nicotine addiction
03/09/2005EP1512413A2 Pharmaceutical combination containing a 4-quinazolineamine and another anti-neoplastic agent for the treatment of cancer
03/09/2005EP1512408A1 Antibacterial agent and antibacterial composition
03/09/2005EP1512405A1 Chloasma amelioration composition and dullness amelioration composition
03/09/2005EP1512404A1 External preparations for treating dermatitis
03/09/2005EP1512403A1 Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof
03/09/2005EP1512402A1 Inhibitors against complex ii of electron transport system
03/09/2005EP1512401A1 Enhancement of bone growth and inhibition of bone resorption
03/09/2005EP1512400A1 Treatment of neurodegenerative diseases
03/09/2005EP1512399A1 Porphyrin oxygen infusion preparation for increasing oxygen concentration in tumor tissue
03/09/2005EP1512398A1 Intravascular stent with cytoskeletal inhibitors for the prevention of restenosis
03/09/2005EP1512397A1 O-substituted hydroxyaryl derivatives
03/09/2005EP1512396A1 Inhibitors against the activation of ap-1 and nfat
03/09/2005EP1512394A1 Universal controlled-release composition comprising chitosan
03/09/2005EP1511845A2 Immunostimulatory oligonucleotides and uses thereof
03/09/2005EP1511811A2 Oil-soluble pigment compositions
03/09/2005EP1511774A1 Per (3,6-anhydro) cyclodextrin derivatives, their preparation and use thereof for separating ions, in particular chromium and manganese anions
03/09/2005EP1511770A2 Immunoadhesin comprising a glycoprotein vi domain
03/09/2005EP1511759A1 Modulators and inhibitors of fibroblast growth factor receptor 5-polypeptides and gene expression thereof.
03/09/2005EP1511757A1 New compounds for modulating the activity of exchange proteins directly activated by camp (epacs)
03/09/2005EP1511756A2 Gangliosides with a modified acyl function
03/09/2005EP1511752A2 Camptothecins with a modified lactone ring
03/09/2005EP1511751A1 Pyrazolo[1,5-a]pyrimidine compounds as antiviral agents
03/09/2005EP1511750A1 Process for the preparation of famciclovir
03/09/2005EP1511748A1 8-fluorimidazo(1,2-a)pyridine derivatives as ligands for gaba receptors
03/09/2005EP1511747A1 Imidazo-pyridine derivatives as ligands for gaba receptors
03/09/2005EP1511745A2 Protease inhibitors
03/09/2005EP1511744A2 Bis-benzimidazoles and related compounds as potassium channel modulators
03/09/2005EP1511743A1 Pyrazole-derivatives as p38 kinase inhibitors
03/09/2005EP1511742A1 Kinase inhibitors
03/09/2005EP1511741A1 Ester derivatives of a decahydroisoquinoline-3-carboxylic acid as analgestics
03/09/2005EP1511740A1 Phenyl-thiophene type vitamin d receptor modulators
03/09/2005EP1511739A1 Polymorphs of valsartan
03/09/2005EP1511738A1 Treatment of fibroproliferative disorders using tgf-beta inhibitors
03/09/2005EP1511737A1 Aryloximes
03/09/2005EP1511736A1 Therapeutic molecules and methods-1
03/09/2005EP1511735A1 Imidazole compounds and their use as ligands of the alpha-" adrenoreceptors
03/09/2005EP1511734A2 Compounds, compositions, and methods
03/09/2005EP1511732A1 Process for the manufacture of quinoline derivatives
03/09/2005EP1511730A2 Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
03/09/2005EP1511728A2 Oxophenyl-cyclohexyl-propanolamine derivatives, production and use thereof in therapeutics
03/09/2005EP1511727A2 Aromatic sulfones and their medical use
1 ... 4761 4762 4763 4764 4765 4766 4767 4768 4769 4770 4771 4772 4773 4774 4775 4776 4777 4778 4779 4780 4781 ... 7860